Hosted on MSN2mon
Amgen gets U.K. approval for tarlatamab for small cell lung cancer
The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Amgen's (NASDAQ:AMGN) tarlatamab, also known as Imdyllytra, for the treatment of small cell lung cancer that has spread ...
Hosted on MSN10mon
FDA approves Imdelltra for patients with extensive-stage small cell lung cancer
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...
pharmaphorum4d
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.
pharmaphorum10mon
Amgen adds BiTE to its cancer range as FDA clears Imdelltra
Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority review. Tarlatamab has been ...